Since proteinuria and hypertension are recapitulated in patients developing toxicity following treatment with VEGF-inhibiting agents (e.g., anti-VEGF antibodies and Fc-VEGFR-dimers) and in a VEGF deletion model [12,13], the glomerulotoxic effects of excess sFLT1 levels are well supported. This evidence concerns the gene VEGFA and hypertensive disorder.